{"disease":{"id":"relapsed-refractory-leukemia","name":"relapsed refractory leukemia"},"drugs":{"marketed":[{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"valemetostat","indication_name":"Relapsed or refractory T-cell leukemia-lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ezharmia","generic_name":"VALEMETOSTAT","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"Histone-lysine N-methyltransferase EZH2","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"chidamide","indication_name":"Relapsed or refractory T-cell leukemia-lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Chidamide","company_name":"Sun Yat-sen University","drug_phase":"phase_3","molecular_target":"Nicotinamide phosphoribosyltransferase, Histone deacetylase 1, Histone deacetylase 10","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ziftomenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Komzifti","generic_name":"ZIFTOMENIB","company_name":"Kura","drug_phase":"marketed","molecular_target":"","drug_class":"Menin Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Komzifti works by inhibiting the menin protein, which is involved in the regulation of gene expression in cancer cells."},{"drug_id":"ziftomenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Komzifti","generic_name":"ZIFTOMENIB","company_name":"Kura","drug_phase":"marketed","molecular_target":"","drug_class":"Menin Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Komzifti works by inhibiting the menin protein, which is involved in the regulation of gene expression in cancer cells."},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"revumenib","indication_name":"relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revuforj","generic_name":"REVUMENIB","company_name":"Syndax","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Revuforj works by inhibiting an enzyme that is involved in the growth and survival of cancer cells."},{"drug_id":"revumenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revuforj","generic_name":"REVUMENIB","company_name":"Syndax","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Revuforj works by inhibiting an enzyme that is involved in the growth and survival of cancer cells."},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":36,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02013167","title":"Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":405,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03886831","title":"A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":232,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT05456048","title":"Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML","phase":"","overall_status":"COMPLETED","enrollment_count":231,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT02783651","title":"An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US","phase":"","overall_status":"COMPLETED","enrollment_count":212,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06472128","title":"Novel Digital Application for Patients With Acute Leukemia","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03504410","title":"Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":200,"lead_sponsor_name":"Cornerstone Pharmaceuticals","has_results":true},{"nct_id":"NCT06084819","title":"Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT07084584","title":"An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":184,"lead_sponsor_name":"Galecto Biotech AB","has_results":false},{"nct_id":"NCT04703192","title":"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT04404660","title":"A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":153,"lead_sponsor_name":"Autolus Limited","has_results":false},{"nct_id":"NCT05621148","title":"REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"French Innovative Leukemia Organisation","has_results":false},{"nct_id":"NCT02675452","title":"AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":141,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06581081","title":"Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia","phase":"NA","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT02825836","title":"Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"Telios Pharma, Inc.","has_results":false},{"nct_id":"NCT04824794","title":"GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":130,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT02614066","title":"A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT06549790","title":"Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"Nerviano Medical Sciences","has_results":false},{"nct_id":"NCT06714591","title":"Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT06547528","title":"A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Ono Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03250338","title":"Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Arog Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03932331","title":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":105,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT00963105","title":"Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT04872621","title":"Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation","phase":"","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07134088","title":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05061147","title":"A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Maxinovel Pty., Ltd.","has_results":false},{"nct_id":"NCT04684147","title":"Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Juventas Cell Therapy Ltd.","has_results":false},{"nct_id":"NCT05334823","title":"A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT06179524","title":"CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Beijing Yongtai Ruike Biotechnology Company Ltd","has_results":false},{"nct_id":"NCT07188610","title":"PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT02625480","title":"Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Kite, A Gilead Company","has_results":false},{"nct_id":"NCT03206918","title":"Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT02228096","title":"Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03765541","title":"Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":73,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT04609241","title":"CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06812104","title":"Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT03218683","title":"Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":70,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04113616","title":"An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":70,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06536959","title":"VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"Beijing 302 Hospital","has_results":false},{"nct_id":"NCT02412306","title":"Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06644183","title":"Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Jennifer R. Brown, MD, PhD","has_results":false},{"nct_id":"NCT03541369","title":"Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":64,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04797767","title":"Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT03755154","title":"Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":60,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT06399640","title":"Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Vanderbilt-Ingram Cancer Center","has_results":false},{"nct_id":"NCT06869265","title":"Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04541277","title":"Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":55,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT04305444","title":"Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":55,"lead_sponsor_name":"Zhejiang DTRM Biopharma","has_results":false},{"nct_id":"NCT06532058","title":"Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":53,"lead_sponsor_name":"Changzhou Qianhong Bio-pharma Co., Ltd.","has_results":false},{"nct_id":"NCT05362942","title":"Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":52,"lead_sponsor_name":"Beijing 302 Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}